The DSIR-approved research laboratory is equipped with the latest molecular and formulation research tools
ENTOD Pharmaceuticals has inaugurated its state-of-the-art research & development centre in Navi Mumbai. The DSIR-approved research laboratory is equipped with the latest molecular and formulation research tools, microbiology testing facilities, sterile batch production capacity, and high-end Quality Assurance/Quality Control analytical equipment.
The new R&D centre underscores ENTOD’s commitment to pioneering pharmaceutical innovation, contributing to India’s aspirations to become a value-driven innovation hub in the speciality pharmaceutical space. The facility will focus on developing next-generation molecules using generative AI platforms, particularly in the ophthalmic, ENT, Paediatrics and skin care segments. Some of these groundbreaking molecules are expected to be indigenous to India, marking a significant stride towards global pharmaceutical leadership.
Kishore Masurkar, Chairman, ENTOD Pharmaceuticals, stated, “Beyond its cutting-edge technology, the R&D centre is a significant step forward in achieving our mission to save and sustain lives. By addressing unmet needs through innovation, we aim to make a lasting impact on patients not only in India but throughout the world. The inauguration heralds a new era where healthcare boundaries are pushed for the greater good.”
Bharati S Jadhav, Senior Scientific Manager, Entod Pharmaceuticals, expressed her enthusiasm, saying, “ENTOD is proud to contribute to India’s pharmaceutical innovation journey. This facility reflects our dedication to pioneering research, ultimately shaping the future of healthcare in India.”
Dhananjay Thakur, Head of Quality Assurance at ENTOD Pharmaceuticals added “The inauguration of our advanced R&D Centre signifies a commitment to innovation and research-driven healthcare. We envision this facility as a nucleus for transformative discoveries, where our team will work relentlessly to develop pharmaceutical solutions that redefine healthcare norms. This endeavour aligns with our larger mission of placing India at the forefront of pharmaceutical innovation globally.”
